ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL CANCER INSTITUTE

Assessment of strategies for targeting transcriptional co-activators in colorectal cancer

Active
Institution
University of Nebraska Medical Center, NE
Principal investigator
Kurt Fisher
Funding
$446K
Duration
2024–2029
Open portfolio

Moonbase score

Still being scored

Abstract

Project Summary: PGC-1 family proteins (PGC-1α, PGC-1β, and PPRC1) are transcriptional coactivators that act as central hubs to coordinate diverse cellular inputs to promote the transcription of genes that regulate metabolism to maintain homeostasis. Transcriptional coactivator Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 β (PGC-1β) is over-expressed in colorectal cancers (CRC) with K-Ras mutations and promotes the survival of tumor cells. PGC-1 family proteins lack intrinsic enzymatic activity and function by facilitating interactions between transcription factors, epigenetic modifiers, and transcription initiation machinery. To identify the protein-protein interactions required by PGC-1β to promote gene expression we immunoprecipitated PGC- 1β and identified binding partners by mass spectrometry. Our data reveal that Estrogen-Related Receptor α (ERRα) and Host Cell Factor 2 (HCF2) are PGC-1β binding proteins that we propose are required for PGC-1β to regulate the transcription of genes that promote CRC survival. Our long-term goal is to inhibit CRC growth by blocking PGC-1β signaling and we propose that can be achieved by preventing PGC-1β from signaling through either ERRα or HCF2. In Aim 1, we will determine the mechanism by which phosphatase PGAM5 modifies PGC-1β to increase ERRα transcription. In Aim 2, we will identify PGC-1β-HCF2 regulated genes and determine the requirements for HCF2 signaling. In Aim 3, we will test the loss of the PGC-1β, the loss of the PGC-1β-ERRα interaction, the loss of the PGC-1β-HCF2 interaction, and the loss of both interactions in vivo using orthotopic submucosal injections in immunodeficient mice receiving Crispr-Cas9-modified patient-derived tumor organoids establish from liver metastases.

LOADING MOONBASE SCORE

NATIONAL CANCER INSTITUTER37Gene Regulation in Cancer Study Section[GRIC]transcriptionaltranscriptioncrcfamily proteinssignaling aimpgcpgc-colorectal

Questions for University of Nebraska Medical Center

Answered by the team behind this research.

Same institution, same topic, scored first.